Table 1 Clinical characteristics of 320 pediatric ALL patients with 6-MP maintenance therapy according to their pharmacogenetic subgroups of NUDT15, TPMT, CRIM1, and IL6 genes.

From: Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT

Characteristics

All WTs

N = 115

NUDT15 or TPMT Non-WT

N = 80†

NUDT15 and TPMT both WTs

N = 125

WTs for all of NUDT15, TPMT, CRIM1, and IL6

NUDT15 non-WT†

TPMT non-WT†

CRIM1 rs3821169 heterozygote only

IL6 rs13306435 heterozygote only

CRIM1 rs3821169 homozygote only

IL6 and CRIM1 hetero- or homozygote

No. of subjects

115 (35.94%)

72 (22.50%)

9 (2.81%)

94 (39.17%)

12 (5.00%)

11 (4.38%)

8 (3.33%)

Age, median (range, year)

5.3 (1.2–19.4)

4.6 (1.7–15.8)

3.6 (1.3–14.8)

5.7 (1.1–17.0)

5.1 (2.4–17.0)

5.9 (2.8–21.8)

3.8 (1.7–7.9)

Sex

       

Male

58

43

6

63

8

7

1

Female

57

29

3

31

4

4

7

Risk group

       

Standard-risk

73

46

4

59

8

8

4

High-risk

42

26

5

35

4

3

4

Last-cycle 6-MP dose intensity percentage, (%)

 ~ 10

2 (1.7%)

9 (12.5%)

0 (0.0%)

2 (2.1%)

1 (8.3%)

2 (18.2%)

1 (12.5%)

10–15

1 (0.9%)

3 (4.2%)

1 (11.1%)

1 (1.1%)

0 (0.0%)

1 (9.1%)

1 (12.5%)

15–25

4 (3.5%)

9 (12.5%)

1 (11.1%)

2 (2.1%)

0 (0.0%)

1 (9.1%)

2 (25.0%)

25–35

5 (4.4%)

7 (9.7%)

1 (11.1%)

9 (9.6%)

1 (8.3%)

2 (18.2%)

3 (37.5%)

35–45

5 (4.4%)

9 (12.5%)

1 (11.1%)

5 (5.3%)

0 (0.0%)

2 (18.2%)

1 (12.5%)

45–60

26 (22.6%)

11 (15.3%)

1 (11.1%)

16 (17.0%)

4 (33.3%)

0 (0.0%)

0 (0.0%)

60–80

31 (27.0%)

14 (19.4%)

2 (22.2%)

32 (34.0%)

2 (16.7%)

0 (0.0%)

0 (0.0%)

80–100

23 (20.0%)

7 (9.7%)

1 (11.1%)

13 (13.8%)

4 (33.3%)

3 (27.3%)

0 (0.0%)

100–

18 (15.7%)

3 (4.2%)

1 (11.1%)

14 (14.9%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

Total

115 (100.0%)

72 (100.0%)

9 (100.0%)

94 (100.0%)

12 (100.0%)

11 (100.0%)

8 (100.0%)

Average ± SD (%)

71.31 ± 29.55

47.14 ± 30.48

56.56 ± 33.62

68.07 ± 28.39

61.59 ± 25.13

42.30 ± 34.97

22.86 ± 9.76

  1. ALL acute lymphoblastic leukemia, 6-MP 6-mercaptopurine, WT wild-type, SD standard deviation.
  2. †One subject showed non-WT characterization for both NUDT15 and TPMT genes. Values are the number of subjects (percentage) unless specified. Age means the age at the start of 6-MP maintenance therapy.
Back to article page